The state of the art of tumor molecular imaging targeting PD-1/PD-L1 pathway / 中华核医学与分子影像杂志

ABSTRACT

Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) path-way has emerged as a critical target for cancer immunotherapy,and monoclonal antibodies that block either side of this inhibitory interaction have demonstrated impressive activity across a broad set of cancer subtypes.Clinical studies have shown that tumor PD-L1 expression is associated with clinical stages and poor prognosis.Tumor PD-L1 expression detection may help to screen the patients who are most likely to be benefit from anti-PD-1/PD-L1 therapy and evaluate the prognosis.Molecular imaging technology such as PET,SPECT and optical imaging may be the modalities that allowing for noninvasively dynamic detection and overall evaluation of multiple biomarkers.This review focuses on the state of the art of tumor molecular imaging targeting PD-1/PD-L1 pathway.